Meningococcal Vaccines Market Size Is Projected to Reach US$ 9.37 Billion by 2026

Pune, India -- (SBWire) -- 05/30/2019 --The Global Meningococcal Vaccines Market Size is anticipated to reach USD 9.37 Billion by 2026 and expected to grow at a CAGR of 12.3% during the forecast period 2019 to 2026.

vaccines are utilized in the treatment of meningitis, septicemia, meningococcemia, and pneumonia. Meningitis is portrayed by the aggravation of the films covering the cerebrum and spinal line. This kind of irritation is brought about by the disease of microscopic organisms, infections, and medications. Meningococcal immunization alludes to any of the vaccines used to forestall contamination by Neisseria meningitides. The vaccines are somewhere in the range of 85 and 100% viable for no less than two years. They result in abatement in meningitis and sepsis among populaces where they are broadly utilized. They are given either by infusion into a muscle or simply under the skin.

Free Download Sample Report Pages for Better understanding@ https://www.acumenresearchandconsulting.com/request-sample/1397

Assembling quality vaccines at moderate costs, different open private organizations for doing innovative work exercises and nearness of vaccines in the pipeline and their normal commercialization, for example, MenACWY is the key variables driving the growth of meningococcal vaccines market over the conjecture time frame. Developing occurrences and death rates due to meningococcal illnesses have made the national government include and support R&D activities and appropriation of meningococcal vaccines. For example, the presentation of Mena Conjugate Vaccine Programs in Africa is required to forestall 123,000 passings by 2018.

ongoing time, expanded government support is a key driver for the worldwide meningococcal vaccines market. Different government affiliations have propelled command inoculation programs for younger students. This expands the interest for meningococcal vaccines to give insusceptibility against meningococcal infection. In any case, stringent guidelines hamper the growth of the worldwide meningococcal vaccines market. Expanding mergers and acquisitions between assembling organizations and government bodies and fast item dispatches are a portion of the significant patterns of the worldwide meningococcal vaccines market.

The global meningococcal vaccines market is segmented into type, end user, and region. On the basis of type, the global market is segmented into combination vaccines (menhibrix and menitorix), conjugate vaccines (menactra, menafrivac, meningitec, menjugate, menveo, neisvac-c, nimenrix, and nmvac4-dt), polysaccharide (mencevax, menomune, nmvac4, and others), men b vaccines (bexsero and trumenba), and others. On the basis of end user, the global market is segmented into retail pharmacies, hospital pharmacies, and others. On the basis of geography, the global market is segment into North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa.

The conjugate vaccines market is required to observe worthwhile growth over the figure time frame inferable from the nearness of high neglected needs and the absence of accessibility of elective vaccines. Different brands, for example, Menactra, Menveo, Trumenba and Mentlibrix and Menoveo are accessible in the market for the treatment of meningococcal. Menactra is authorized for the organization in the age bunch from 9 months to 55 years of age. MPSV4 is the main antibody affirmed for use in individuals over 55 years just as for 2 to 55 yrs. Novartis created Baxsero which is an affirmed conjugate antibody has demonstrated value in the treatment of meningitis and is the first Serogroup B antibody to be incorporated into the national inoculation program.

View Detail Information with Complete TOC@ https://www.acumenresearchandconsulting.com/meningococcal-vaccines-market

North America market is anticipated to be a conspicuous market, all-inclusive, as far as income, before the finish of 2028. In North America and Europe, because of government intercession regarding enactment, vaccination projects and mindfulness battles, occurrences of meningitis have decreased altogether. As per a report by the U.S. Habitats for Disease Control and Prevention (CDC), 1,000 to 2,600 individuals contract the meningococcal infection every year in the U.S., while in Africa, it is evaluated to be 1,000 cases for each 100,000 populace. The market in the Asia Pacific is required to extend at a fast pace, trailed by the market in Rest of the World during the conjecture time frame. Variables driving the market in the Asia Pacific incorporate a ceaseless ascent in populace base, cyclic events of meningococcal ailment episodes before, and expanded spotlight on preventive measures against the horrible illnesses. The beginning of late patterns, for example, enrolment of drug specialists in preparing programs, directed by the New Zealand Ministry of Health, is likewise boosting the market.

Major companies contributing the global meningococcal vaccines market are Baxter International, Biomed Pvt. Ltd., GlaxoSmithKline plc, JN-International Medical Corporation, Novartis International, Nuron Biotech, Pfizer Inc., Sanofi SA, and Serum Institute of India Ltd.

Browse all official Market Research Reports Press Releases@ https://www.acumenresearchandconsulting.com/press-releases

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Meningococcal Vaccines
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Meningococcal Vaccines Market By Type
1.2.2.1. Global Meningococcal Vaccines Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.2.2. Global Meningococcal Vaccines Market Revenue Share By Type in 2017
1.2.2.3. Combination Vaccines
1.2.2.3.1. MenHibrix
1.2.2.3.2. Menitorix
1.2.2.4. Conjugate Vaccines
1.2.2.4.1. Menactra
1.2.2.4.2. MenAfriVac
1.2.2.4.3. Meningitec
1.2.2.4.4. Menjugate
1.2.2.4.5. Menveo
1.2.2.4.6. NeisVac-C
1.2.2.4.7. Nimenrix
1.2.2.4.8. NmVac4-DT
1.2.2.5. Polysaccharide
1.2.2.5.1. Mencevax
1.2.2.5.2. Menomune
1.2.2.5.3. NmVac4
1.2.2.5.4. Others
1.2.2.6. Men B Vaccines
1.2.2.6.1. Bexsero
1.2.2.6.2. Trumenba
1.2.2.6.3. Others
1.2.3. Meningococcal Vaccines Market By End User
1.2.3.1. Global Meningococcal Vaccines Market Revenue and Growth Rate Comparison By End User (2015-2026)
1.2.3.2. Global Meningococcal Vaccines Market Revenue Share By End User in 2017
1.2.3.3. Retail Pharmacies
1.2.3.4. Hospital Pharmacies
1.2.3.5. Others
1.2.4. Meningococcal Vaccines Market by Geography
1.2.4.1. Global Meningococcal Vaccines Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.4.2. North America Meningococcal Vaccines Market Revenue and Growth Rate (2015-2026)
1.2.4.3. Europe Meningococcal Vaccines Market Revenue and Growth Rate (2015-2026)
1.2.4.4. Asia-Pacific Meningococcal Vaccines Market Revenue and Growth Rate (2015-2026)
1.2.4.5. Latin America Meningococcal Vaccines Market Revenue and Growth Rate (2015-2026)
1.2.4.6. Middle East and Africa (MEA) Meningococcal Vaccines Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter's Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Meningococcal Vaccines Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Meningococcal Vaccines Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Meningococcal Vaccines Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Meningococcal Vaccines Major Manufacturers in 2017

CHAPTER 4. MENINGOCOCCAL VACCINES MARKET BY FORM

4.1. Global Meningococcal Vaccines Revenue By Type
4.2. Combination Vaccines
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Conjugate Vaccines
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Polysaccharide
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Men B Vaccines
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. MENINGOCOCCAL VACCINES MARKET BY END USER

5.1. Global Meningococcal Vaccines Revenue By End User
5.2. Retail Pharmacies
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Hospital Pharmacies
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Others
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET BY COUNTRY

6.1. North America Meningococcal Vaccines Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2. North America Meningococcal Vaccines Market Revenue Share Comparison, 2015 & 2026 (%)
6.3. U.S.
6.3.1. U.S. Meningococcal Vaccines Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
6.4. Canada
6.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
6.5. Mexico
6.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)

CHAPTER 7. EUROPE MENINGOCOCCAL VACCINES MARKET BY COUNTRY

7.1. Europe Meningococcal Vaccines Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. Europe Meningococcal Vaccines Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. UK
7.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
7.4. Germany
7.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
7.5. France
7.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
7.6. Spain
7.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.6.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
7.7. Rest of Europe
7.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.7.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)

CHAPTER 8. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET BY COUNTRY

8.1. Asia-Pacific Meningococcal Vaccines Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Asia-Pacific Meningococcal Vaccines Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. China
8.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
8.4. Japan
8.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
8.5. India
8.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
8.6. Australia
8.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
8.7. South Korea
8.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
8.8. Rest of Asia-Pacific
8.8.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.8.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)

CHAPTER 9. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET BY COUNTRY

9.1. Latin America Meningococcal Vaccines Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Latin America Meningococcal Vaccines Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. Brazil
9.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
9.4. Argentina
9.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
9.5. Rest of Latin America
9.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)

CHAPTER 10. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET BY COUNTRY

10.1. Middle East Meningococcal Vaccines Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Middle East Meningococcal Vaccines Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Saudi Arabia
10.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
10.4. UAE
10.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
10.5. Rest of Middle East
10.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)

CHAPTER 11. AFRICA MENINGOCOCCAL VACCINES MARKET BY COUNTRY

11.1. Africa Meningococcal Vaccines Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Africa Meningococcal Vaccines Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. South Africa
11.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
11.4. Egypt
11.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
11.5. Rest of Africa
11.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)

CHAPTER 12. COMPANY PROFILE

12.1. Baxter International
12.1.1. Company Snapshot
12.1.2. Overview
12.1.3. Financial Overview
12.1.4. Product Portfolio
12.1.5. Key Developments
12.1.6. Strategies
12.2. Biomed Pvt. Ltd.
12.2.1. Company Snapshot
12.2.2. Overview
12.2.3. Financial Overview
12.2.4. Product Portfolio
12.2.5. Key Developments
12.2.6. Strategies
12.3. GlaxoSmithKline plc
12.3.1. Company Snapshot
12.3.2. Overview
12.3.3. Financial Overview
12.3.4. Product Portfolio
12.3.5. Key Developments
12.3.6. Strategies
12.4. JN-International Medical Corporation
12.4.1. Company Snapshot
12.4.2. Overview
12.4.3. Financial Overview
12.4.4. Product Portfolio
12.4.5. Key Developments
12.4.6. Strategies
12.5. Novartis International
12.5.1. Company Snapshot
12.5.2. Overview
12.5.3. Financial Overview
12.5.4. Product Portfolio
12.5.5. Key Developments
12.5.6. Strategies
12.6. Nuron Biotech
12.6.1. Company Snapshot
12.6.2. Overview
12.6.3. Financial Overview
12.6.4. Product Portfolio
12.6.5. Key Developments
12.6.6. Strategies
12.7. Pfizer Inc.
12.7.1. Company Snapshot
12.7.2. Overview
12.7.3. Financial Overview
12.7.4. Product Portfolio
12.7.5. Key Developments
12.7.6. Strategies
12.8. Sanofi SA
12.8.1. Company Snapshot
12.8.2. Overview
12.8.3. Financial Overview
12.8.4. Product Portfolio
12.8.5. Key Developments
12.8.6. Strategies
12.9. Serum Institute of India Ltd
12.9.1. Company Snapshot
12.9.2. Overview
12.9.3. Financial Overview
12.9.4. Product Portfolio
12.9.5. Key Developments
12.9.6. Strategies
12.10. Others
12.10.1. Company Snapshot
12.10.2. Overview
12.10.3. Financial Overview
12.10.4. Product Portfolio
12.10.5. Key Developments
12.10.6. Strategies

CHAPTER 13. RESEARCH APPROACH

13.1. Research Methodology
13.1.1. Initial Data Search
13.1.2. Secondary Research
13.1.3. Primary Research
13.2. Assumptions and Scope

INQUIRY BEFORE BUYING@ https://www.acumenresearchandconsulting.com/inquiry-before-buying/1397

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this Premium Research Report - https://www.acumenresearchandconsulting.com/buy-now/0/1397

Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157

About Acumen Research and Consulting:
Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.